Myelofibrosis: In Search for BETter Targeted Therapies

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. March 07, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00833 Journal of Clinical Oncology - published online before print September 26, 2023 PMID: 37751563 Myelofibrosis: In Search for BETter Targeted Therapies Giuseppe A. Palumbo , MD, PhD1xGiuseppe A. PalumboSearch for articles by this author and Andrea Duminuco , MD2,3xAndrea DuminucoSearch for articles by this author Show More 1Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia,” University of Catania, Catania, Italy2Postgraduate School of Hematology, University of Catania, Catania, Italy3Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom https://doi.org/10.1200/JCO.23.00833 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTMyelofibrosis: In Search for BETter Targeted TherapiesThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Giuseppe A. PalumboConsulting or Advisory Role: Novartis, AOP Orphan Pharmaceuticals, AbbVie, AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, MorphosysSpeakers' Bureau: Novartis, Celgene/Bristol Myers Squibb, AbbVieTravel, Accommodations, Expenses: Takeda, Novartis, AbbVie, BeiGene, JanssenAndrea DuminucoHonoraria: EUSA Pharma, Celgene/Bristol Myers SquibbNo other potential conflicts of interest were reported. Companion MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis